Valerio Therapeutics

📍 Paris, France🗓 Founded 2014👥 49 employees💰 Last funded Jun 2022
Pharmaceutical Manufacturing🌐 valeriotx.com
Website LinkedIn
Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on intracellular DNA-binding targets, we design and develop first-in-class treatments for oncology and inflammatory diseases precision therapeutics from preclinical (translational) research to human clinical proof-of-concept studies. It thus leads its programs to the most value-creating and attractive inflection points for potential partners. The Companys portfolio is based on platON™, Valerio Therapeutics decoy oligonucleotide platform. PlatON™ is intended to generate new compounds based on an unparalleled DDR decoy mechanism and capitalizing on the expertise the Company has developed on this type of oligonucleotides. The Companys portfolio includes: - AsiDNA™, a first-in-class product interfering with tumor DNA break repair, based on a decoy agonist mechanism, unmatched in the DDR field, which could, among other things, combat tumor resistance. AsiDNA™ is in clinical development in several trials, in combination with PARP inhibitors or in combination with radiation therapy. - A new family of compounds are positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. VIO-01, is currently being optimized in a preclinical phase. The Company is convinced of the significant therapeutic potential of its technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer and inflammatory disease treatments.
3
Total investors
0
Early stage
0
Mid stage
3
Late stage
2014
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
2
United States
1
Investor activity2020–2022 · investors recorded per year
202012021120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Valerio Therapeutics?
Valerio Therapeutics has 3 investors on record on gritt.io and 3 late-stage investors.
When did Valerio Therapeutics last raise funding?
The most recent investment in Valerio Therapeutics recorded on gritt.io was in June 2022.
When was Valerio Therapeutics founded?
Valerio Therapeutics was founded in 2014.
What industry is Valerio Therapeutics in?
Valerio Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Valerio Therapeutics based?
Valerio Therapeutics is headquartered in Paris, France.